文献速递神经肿瘤

为脑肿瘤手术点亮灯光:5-氨基乙酰丙酸的故事

Turning on the light for brain tumor surgery: A 5-aminolevulinic acid story.
PubMed 文献 · Neuro Oncol · 2022-01-01

本文综述5-氨基乙酰丙酸(5-ALA)荧光引导手术在脑肿瘤手术中的应用背景、临床证据与未来方向。5-ALA是美国食品药品监督管理局(FDA)唯一批准用于胶质瘤手术识别肿瘤组织的光学成像剂;一项多中心随机对照试验显示5-ALA荧光引导手术几乎使肿瘤切除范围加倍,并改善6个月无进展生存期(PFS)。最大安全切除仍是多数脑肿瘤的标准治疗。

要点

  • 5-ALA是FDA唯一批准用于胶质瘤手术识别肿瘤组织的光学成像剂。
  • 多中心随机对照试验显示5-ALA荧光引导手术几乎使肿瘤切除范围加倍。
  • 该试验还显示5-ALA荧光引导手术改善6个月无进展生存期(PFS)。

核心结论

  • 5-ALA荧光引导手术是脑肿瘤手术中辅助识别肿瘤组织的技术,最大安全切除仍是多数脑肿瘤的标准治疗。

研究设计与样本

  • 本文为综述,描述5-ALA融入现代神经外科实践的背景、当前临床证据及未来方向。

主要发现

  • 5-ALA是FDA唯一批准用于胶质瘤手术识别肿瘤组织的光学成像剂。
  • 一项多中心随机对照试验显示5-ALA荧光引导手术几乎使肿瘤切除范围加倍,并改善6个月无进展生存期(PFS)。
  • 高级别胶质瘤(HGG)全切除与次全切除或仅辅助治疗相比,与更高的总生存期和无进展生存期(PFS)相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To aid surgeons in more complete and safe resection of brain tumors, adjuvant technologies have been developed to improve visualization of target tissue. Fluorescence-guided surgery relies on the use of fluorophores and specific light wavelengths to better delineate tumor tissue, inflammation, and areas of blood-brain barrier breakdown. 5-aminolevulinic acid (5-ALA), the first fluorophore developed specifically for brain tumors, accumulates within tumor cells, improving visualization of tumors both at the core, and infiltrative margin. Here, we describe the background of how 5-ALA integrated into the modern neurosurgery practice, clinical evidence for the current use of 5-ALA, and future directions for its role in neurosurgical oncology. Maximal safe resection remains the standard of care for most brain tumors. Gross total resection of high-grade gliomas (HGGs) is associated with greater overall survival and progression-free survival (PFS) in comparison to subtotal resection or adjuvant treatment therapies alone.1-3 A major challenge neurosurgeons encounter when resecting infiltrative gliomas is identification of the glioma tumor margin to perform a radical resection while avoiding and preserving eloquent regions of the brain. 5-aminolevulinic acid (5-ALA) remains the only optical-imaging agent approved by the FDA for use in glioma surgery and identification of tumor tissue.4 A multicenter randomized, controlled trial revealed that 5-ALA fluorescence-guided surgery (FGS) almost doubled the extent of tumor resection and also improved 6-month PFS.5 In this review, we will highlight the current evidence for use of 5-ALA FGS in brain tumor surgery, as well as discuss the future directions for its use.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. McCracken DJ, Schupper AJ, Lakomkin N, et al. Turning on the light for brain tumor surgery: A 5-aminolevulinic acid story. Neuro Oncol. 2022. PMID: 36322101. doi:10.1093/neuonc/noac191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。